In this work, we examined the impact of selective stimulation of V2r on key cellular events related to tumor progression through the use of the two analogs V2r agonists, dDAVP and [V4Q5]dDAVP, of the neuropeptide AVP, on lung and prostate tumor lines with NE phenotypes. The gene discussed is AVP; the disease is prostate neoplasm.